Crystal Pharmatech

Crystal Pharmatech is a specialized CRO/CDMO founded in 2010 that excels in crystal form and formulation services for small‑molecule drugs. With a global footprint that includes cGMP facilities in the United States, Canada, and China, the company has supported over 1,000 clients and more than 2,000 compounds, delivering expertise in solid‑state research, crystallization, pre‑formulation, formulation development, and manufacturing. Their integrated service portfolio spans developability assessment, solid‑form screening, formulation, and commercial manufacturing, all compliant with FDA, EMA, and NMPA standards. A distinctive feature is the Mol2Med program, a three‑step First‑Time‑Right approach that expedites lead compounds from optimization to Phase I by ensuring robust API forms and scalable processes. Crystal Pharmatech’s culture of precision, collaboration, and regulatory excellence positions it as a trusted partner for efficient, high‑quality drug development.